The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.
 
Emilie Le Rhun
Honoraria - Mundipharma; Novartis
Consulting or Advisory Role - Abbvie; Daiichi Sankyo
Research Funding - Amgen (Inst); Mundipharma (Inst)
 
Els Genbrugge
No Relationships to Disclose
 
Roger Stupp
Employment - Celgene (I)
Stock and Other Ownership Interests - Celgene (I)
Consulting or Advisory Role - Celgene (Inst); Debiopharm Group (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); UCB (Inst)
Travel, Accommodations, Expenses - Novocure
 
Olivier L. Chinot
Honoraria - Abbvie; Bristol-Myers Squibb; Immatics; IPSEN; SERVIER
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Roche
Research Funding - Roche
Patents, Royalties, Other Intellectual Property - Patent with aix Marseille University on the use of mmp as biomarkers to predict the benefit of anti angiogenic agents
Travel, Accommodations, Expenses - SERVIER
 
Louis B. Nabors
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Speakers' Bureau - Merck/Schering Plough
Travel, Accommodations, Expenses - Merck/Schering Plough
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Alexion Pharmaceuticals; Boston Biomedical; Bristol-Myers Squibb; Celgene; Celldex; cortice; CytRx Corporation; Human Longevity, Inc; Insys Therapeutics; Merck; Nektar; NewGen Therapeutics; Notable Labs; Novartis; Novocure; Novogen; Oxigene; Pfizer; ProNAi; Roche/Genentech; Sunovion; Tocagen; Upsher-Smith; VBL Therapeutics; wellcome trust
 
David A. Reardon
Honoraria - Abbvie; Bristol-Myers Squibb; Bristol-Myers Squibb; Cavion; Celldex; Genentech/Roche; Inovio Pharmaceuticals; Juno Therapeutics; Merck; Midatech Pharma; Momenta Pharmaceuticals; Monteris Medical; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics
Consulting or Advisory Role - Bristol-Myers Squibb; Cavion; Celldex; Genentech/Roche; Inovio Pharmaceuticals; Juno Therapeutics; Merck; Midatech Pharma; Momenta Pharmaceuticals; Monteris Medical; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Celldex (Inst); EMD Serono (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); Midatech Pharma (Inst); Tragara (Inst)
 
Wolfgang Wick
Honoraria - MSD Oncology
Consulting or Advisory Role - Celldex; Roche/Genentech
Research Funding - Apogenix (Inst); Boehringer Ingelheim (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
 
Thierry Gorlia
No Relationships to Disclose
 
Michael Weller
Honoraria - Lilly; Merck Serono; MSD; Novocure; Roche
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Celldex; Lilly; Merck Serono; Pfizer; Roche; Teva
Research Funding - Acceleron Pharma (Inst); Actelion (Inst); Bayer (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novocure (Inst); OGD2 Pharma (Inst); Piqur (Inst); Roche (Inst); Tragara (Inst)